Re-Vana Therapeutics is an ocular pharmaceutical​ and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.


Pharmaceutical

Re-Vana Therapeutics

Michael O’rourke

Gregoire Schwach

Wenrui Zhang

Sandip Gite

Shivanki Sahay

Peter McKenna

Jenna Hewitt

Lucy Finlay

Ravi Deevi

Sangdi Wang

Patrick H O’ruane

Tom Biancardi

Thakur Raghu Raj Singh

David Waite

The founding team at Re-Vana Therapeutics have a long history in the field of pharmaceutics and ocular delivery. They have been lecturers and senior lecturers at Queen's University Belfast for many years, and have also held the position of Chair of the Ocular Delivery Focus Group at the Controlled Release Society. This wealth of experience and knowledge ensures that the company is at the forefront of developing new and innovative ways to deliver drugs to patients.

Founding Team

Board of Directors

Leadership Team

CEO and Executive Team

Founding Team

About

Team members

Other teams at Re-Vana Therapeutics

Board of Directors

Leadership Team

CEO and Executive Team